The main lines of research include: - Nanomaterials as vector systems for therapeutic and diagnostic applications - Development of graphene and 2D materials in medicine - Clinical translation of bioelectronic and microfluidic devices - Discovery of novel biomarkers and therapeutic targets in oncology and neurology The Nanomedicine Group has long-term expertise in research and development of novel types and applications of established nanoparticle systems, particularly liposomes. Moreover, rich experience in the medical translation of carbon nanomaterials, at varying shapes and dimensions, such as fullerenes, carbon nanotubes, nanohorns and graphene. A wide range of nanomaterials developed as platforms for the biological transport of therapeutic and diagnostic components in cell culture and preclinical disease models. The primary therapeutic targets for clinical translation of these technologies have been cancer (solid and metastatic) and brain pathologies (Parkinson’s, stroke, Alzheimers, glioblastoma). Nanomedicine@ICN2 has strong links with the Nanomedicine Lab at the Faculty of Biology, Medicine and Health at the University of Manchester, with Prof. Kostas Kostarelos leading both teams in a joint effort to develop medicines at the nanoscale. Graphene and 2D materials will have a central role in a number of research lines carried out in the context of the Graphene Flagship Biomedical Technologies Work Package.